1. Home
  2. INTT vs KZIA Comparison

INTT vs KZIA Comparison

Compare INTT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$11.14

Market Cap

139.2M

Sector

Technology

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$12.48

Market Cap

154.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
KZIA
Founded
1981
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.2M
154.5M
IPO Year
1997
2002

Fundamental Metrics

Financial Performance
Metric
INTT
KZIA
Price
$11.14
$12.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$13.50
$19.50
AVG Volume (30 Days)
117.4K
252.2K
Earning Date
05-05-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$66,801,000.00
N/A
Revenue This Year
$15.82
N/A
Revenue Next Year
$9.10
N/A
P/E Ratio
$179.50
N/A
Revenue Growth
66.06
N/A
52 Week Low
$7.07
$4.86
52 Week High
$20.00
$17.40

Technical Indicators

Market Signals
Indicator
INTT
KZIA
Relative Strength Index (RSI) 33.93 43.25
Support Level $7.36 $11.39
Resistance Level $10.88 $14.79
Average True Range (ATR) 0.59 1.22
MACD -0.10 -0.20
Stochastic Oscillator 11.48 1.75

Price Performance

Historical Comparison
INTT
KZIA

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: